(Note: This is not an IPO. This is an up-listing, also known as an uplift or a step-up, to the NASDAQ from the OTCQB Venture Market. IPOScoop has this deal as a No Call. We do not provide SCOOP ratings on step-up listings. From the prospectus: This is an offering of units – not shares. Each unit consists of one share of common stock and one warrant.

(The IPO was downsized by 20 percent at pricing: 1.2 million units priced (vs.1.5 million units in the prospectus) at $4.75 each. Background: In an S-1/A filing dated Nov. 16, the company changed the offering’s terms to 1.5 million units at an assumed price of $4.75 per unit. This was a cut of 24 percent in the deal’s size from its previous terms of 1.5 million shares of common stock at $5.75 to $6.75.  The company’s stock traded under the symbol “LIXT” on the OTCQB, where it was last quoted on Nov. 13 at $1.13, according to the prospectus.)

We are a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. Our product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or X-ray and immune checkpoint blockers.

Our leading product candidates are the LB-100 series, which consists of novel structures which have the potential to be first in their class and may be useful in treating several types of cancer as well as vascular and metabolic diseases, and the LB-200 series, which may be useful in treating chronic hereditary diseases such as Gaucher’s disease, in addition to cancer and neurodegenerative diseases.